No. 25-225

MSN Pharmaceuticals, Inc., et al. v. Novartis Pharmaceuticals Corporation

Lower Court: Federal Circuit
Docketed: 2025-08-26
Status: Denied
Type: Paid
Amici (10)Response RequestedResponse WaivedRelisted (2)
Tags: after-arising-technology claim-construction federal-circuit patent-infringement patent-validity section-112
Key Terms:
Antitrust Patent Privacy JusticiabilityDoctri
Latest Conference: 2025-12-12 (distributed 2 times)
Question Presented (AI Summary)

Whether, in a patent-infringement suit, a court may consider after arising technology to hold that the patent is invalid under § 112(a) of the Patent Act?

Question Presented (OCR Extract)

In a patent case, “after -arising technology” is technology that was not invented until after the patent’s filing. Neither this Court nor the Federal Circuit en banc has addressed the disclosure rules for after -arising technology. One line of Federal Circui t case law holds that when a patentee secures a claim construction that ensnares, as infringing, an accused device that features after -arising technology, the patentee risks invalidating its own patent under 35 U.S.C. § 112(a), which requires a patentee to describe and teach the claimed invention. A contradictory line of Federal Circuit decisions, including the decision below, carves out an exception for after -arising technology. This line holds that “later -existing state of the art … may not be properly considered” in the validity analysis. After -arising technology, that is, may not “reach back and invalidate” a patent. Yet that proposition conflicts with The Incandescent Lamp Patent , 159 U.S. 465 (1895). Edison’s after -arising bamboo -filament technology ex posed the invalidity of Sawyer and Man’s patent for an electric lightbulb . The question presented is: Whether, in a patent -infringement suit, a court may consider after arising technology to hold that the patent is invalid under § 112(a) of the Patent Act?

Docket Entries

2025-12-15
Petition DENIED.
2025-11-25
Reply of petitioners MSN Pharmaceuticals, Inc., et al. filed. (Distributed)
2025-11-25
Reply of MSN Pharmaceuticals, Inc., et al. submitted.
2025-11-25
DISTRIBUTED for Conference of 12/12/2025.
2025-11-07
Brief of respondent Novartis Pharmaceuticals Corporation in opposition filed.
2025-11-07
Brief of Novartis Pharmaceuticals Corporation in opposition submitted.
2025-10-08
Amicus brief of Biophore Pharma Inc.; Natco Pharma Inc.; and Deva Holding A/S submitted.
2025-10-08
Amicus brief of Public Interest Patent Law Institute submitted.
2025-10-08
Amicus brief of Sigmapharm Laboratories, LLC submitted.
2025-10-08
Amicus brief of Professors Jonathan Masur and Lisa Ouellette submitted.
2025-10-08
Brief amicus curiae of Public Interest Patent Law Institute filed.
2025-10-08
Brief amici curiae of Biophore Pharma Inc., et al. filed.
2025-10-08
Brief amicus curiae of Sigmapharm Laboratories, LLC filed.
2025-10-08
Brief amici curiae of Professors Jonathan Masur, et al. filed.
2025-10-08
Brief amici curiae of Intellectual Property Law Professors filed.
2025-10-08
Brief amici curiae of Biophore Pharma, Inc., et al. filed.
2025-10-08
Brief amici curiae of Professor Jonathan Masur, et al. filed.
2025-10-01
Brief amicus curiae of Unified Patents, LLC filed.
2025-10-01
Amicus brief of Unified Patents, LLC submitted.
2025-09-18
Motion to extend the time to file a response is granted and the time is extended to and including November 7, 2025.
2025-09-17
Motion to extend the time to file a response from October 8, 2025 to November 7, 2025, submitted to The Clerk.
2025-09-17
Motion of Novartis Pharmaceuticals Corporation for an extension of time submitted.
2025-09-08
Response Requested. (Due October 8, 2025)
2025-09-04
Letter from counsel of MSN Pharmaceuticals, Inc., et al. received.
2025-09-04
Letter received from MSN Pharmaceuticals, Inc., et al.
2025-09-04
Letter regarding upcoming Amicus Briefs of MSN Pharmaceuticals, Inc., et al. submitted.
2025-09-03
Brief amicus curiae of Association for Accessible Medicines filed. (Distributed)
2025-09-03
Brief amicus curiae of The Association for Accessible Medicines filed. (Distributed)
2025-09-03
Amicus brief of The Association for Accessible Medicines submitted.
2025-09-03
DISTRIBUTED for Conference of 9/29/2025.
2025-09-02
Waiver of right of respondent Novartis Pharmaceuticals Corporation to respond filed.
2025-08-22
Petition for a writ of certiorari filed. (Response due September 25, 2025)
2025-06-11
Application (24A1215) granted by The Chief Justice extending the time to file until August 22, 2025.
2025-06-06
Application (24A1215) to extend the time to file a petition for a writ of certiorari from June 23, 2025 to August 22, 2025, submitted to The Chief Justice.

Attorneys

Biophore Pharma Inc.; Natco Pharma Inc.; and Deva Holding A/S
Shashank S. UpadhyeUpadhye Tang LLP, Amicus
Shashank S. UpadhyeUpadhye Tang LLP, Amicus
Intellectual Property Law Professors
Jeffrey Alan AndrewsYetter Coleman LLP, Amicus
Jeffrey Alan AndrewsYetter Coleman LLP, Amicus
MSN Pharmaceuticals, Inc., et al.
Amit R. VoraKasowitz LLP, Petitioner
Amit R. VoraKasowitz LLP, Petitioner
Novartis Pharmaceuticals Corporation
Deanne Elizabeth MaynardMorrison & Foerster LLP, Respondent
Deanne Elizabeth MaynardMorrison & Foerster LLP, Respondent
Professors Jonathan Masur and Lisa Ouellette
David Jacob ZimmerZimmer, Citron & Clarke LLP, Amicus
David Jacob ZimmerZimmer, Citron & Clarke LLP, Amicus
Public Interest Patent Law Institute
Mark H. RemusCrowell & Moring, Amicus
Mark H. RemusCrowell & Moring, Amicus
Sigmapharm Laboratories, LLC
Adam G. UnikowskyJenner & Block LLP, Amicus
Adam G. UnikowskyJenner & Block LLP, Amicus
The Association for Accessible Medicines
Keith A. ZullowGemini Law LLP, Amicus
Keith A. ZullowGemini Law LLP, Amicus
Unified Patents, LLC
Chad Allen LandmonPolsinelli, Amicus
Chad Allen LandmonPolsinelli, Amicus